The effect of L-carnitine as an adjunct on cognitive abilities of patients with schizophrenia
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20191218045795N8
- Lead Sponsor
- Sanandaj University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Schizophrenia according to DSM-5
Absence of any other disease that negatively affects the patient's cognitive processes (dementia, hypothyroidism, intellectual disability, ID... based on clinical interview)
receiving a fixed dose of drugs such as anticholinergics (bipyridine...) and benzodiazepines during the last 1 month
Receiving regular standard treatment and having a stable and controlled clinical condition during the last 1 month
Coexistence of another psychiatric disorder according to DSM-5
Received ECT in the past 2 months
Coexistence of substance abuse disorder and methadone according to DSM-5
Taking any medication that is prescribed due to cognitive problems or significantly affects the patient's cognitive processes
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Increasing the cognitive abilities of patients with schizophrenia following the administration of L-carnitine. Timepoint: The beginning, middle and end of the study. Method of measurement: Wechsler Memory Scale Questionnaire (WMS) and Brief Mental State Examination (MMSE).
- Secondary Outcome Measures
Name Time Method Changes in CRP serum levels. Timepoint: The beginning and end of the study. Method of measurement: Serum sample collection and quantitative measurement of CRP.